Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Backgrounds/Aims: Liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE) can assess fibrotic burden in chronic liver diseases. The systematic review and meta-analysis was conducted to determine whether LSM using VCTE can predict the risk of development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients. Methods: A systematic literature search of the Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases (from January 2010 to June 2023) was conducted. Of the 1,345 individual studies identified, 10 studies that used VCTE were finally registered. Hazard ratios (HRs) and the 95% confidence intervals (CIs) were considered summary estimates of treatment effect sizes of ≥11 kilopascal (kPa) standard for HCC development. Meta-analysis was performed using the restricted Maximum Likelihood random effects model. Results: Among the ten studies, data for risk ratios for HCC development could be obtained from nine studies. When analyzed for the nine studies, the HR for HCC development was high at 3.33 (95% CI, 2.45–4.54) in CHB patients with a baseline LSM of ≥11 kPa compared to patients who did not. In ten studies included, LSM of ≥11 kPa showed the sensitivity and specificity for predicting HCC development were 61% (95% CI, 50–71%) and 78% (95% CI, 66–86%), respectively, and the diagnostic accuracy was 0.74 (95% CI, 0.70–0.77). Conclusions: The risk of HCC development was elevated in CHB patients with VCTE-determined LSM of ≥11 kPa. This finding suggests that VCTE-determined LSM values may aid the risk prediction of HCC development in CHB patients.
Abstract
Backgrounds/Aims: Liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE) can assess fibrotic burden in chronic liver diseases. The systematic review and meta-analysis was conducted to determine whether LSM using VCTE can predict the risk of development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients. Methods: A systematic literature search of the Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases (from January 2010 to June 2023) was conducted. Of the 1,345 individual studies identified, 10 studies that used VCTE were finally registered. Hazard ratios (HRs) and the 95% confidence intervals (CIs) were considered summary estimates of treatment effect sizes of ≥11 kilopascal (kPa) standard for HCC development. Meta-analysis was performed using the restricted Maximum Likelihood random effects model. Results: Among the ten studies, data for risk ratios for HCC development could be obtained from nine studies. When analyzed for the nine studies, the HR for HCC development was high at 3.33 (95% CI, 2.45–4.54) in CHB patients with a baseline LSM of ≥11 kPa compared to patients who did not. In ten studies included, LSM of ≥11 kPa showed the sensitivity and specificity for predicting HCC development were 61% (95% CI, 50–71%) and 78% (95% CI, 66–86%), respectively, and the diagnostic accuracy was 0.74 (95% CI, 0.70–0.77). Conclusions: The risk of HCC development was elevated in CHB patients with VCTE-determined LSM of ≥11 kPa. This finding suggests that VCTE-determined LSM values may aid the risk prediction of HCC development in CHB patients.
참고문헌 (47)
- Fattovich G, "Natural history of chronic hepatitis B : special emphasis on disease progression and prognostic factors", J Hepatol, 48, pp.335~352 (2008)
- Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B(REACH-B) : development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)
- Korean Liver Cancer Association(KLCA)and National Cancer Center(NCC)Korea, "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Clin Mol Hepatol, 28, pp.583~705 (2022)
- Sarasin FP, "Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis", Am J Med, 101, pp.422~434 (1996)
- Rockey DC, "Liver biopsy", Hepatology, 49, pp.1017~1044 (2009)
- Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
- Regev A, "Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection", Am J Gastroenterol, 97, pp.2614~2618 (2002)
- Piccinino F, "Complications following percutaneous liver biopsy. A multicentre retrospective study on 68, 276 biopsies", J Hepatol, 2, pp.165~173 (1986)
- Colli A, "Severe liver fibrosis or cirrhosis : accuracy of US for detection--analysis of 300 cases", Radiology, 227, pp.89~94 (2003)
- Soresi M, "Non invasive tools for the diagnosis of liver cirrhosis", World J Gastroenterol, 20, pp.18131~18150 (2014)
- Chan HL, "Identifying hepatitis B carriers at low risk for hepatocellular carcinoma", Gastroenterology, 142, pp.1057~1060 (2012)
- Tsochatzis EA, "Elastography for the diagnosis of severity of fibrosis in chronic liver disease : a meta-analysis of diagnostic accuracy", J Hepatol, 54, pp.650~659 (2011)
- Li Y, "Systematic review with meta-analysis : the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B", Aliment Pharmacol Ther, 43, pp.458~469 (2016)
- Singh S, "Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 11, pp.1573~1584 (2013)
- Yoo SH, "Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B", J Viral Hepat, 28, pp.1362~1372 (2021)
- Kim MN, "ALT is not associated with achieving subcirrhotic liver stiffness and HCC during entecavir therapy in HBV-related cirrhosis", Clin Gastroenterol Hepatol, 21, pp.2278~2287 (2023)
- Wong GL, "Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B", J Hepatol, 60, pp.339~345 (2014)
- Kim MN, "Risk assessment of liver-related events using transient elastography in patients with chronic hepatitis B receiving entecavir", J Clin Gastroenterol, 48, pp.272~278 (2014)
- "Cochrane handbook for systematic reviews for interventions, Version 5.1.0"[URL]
- Moher D, "Preferred repor ting items for systematic reviews and meta-analyses : the PRISMA statement", Ann Intern Med, 151, pp.264~269 (2009)
- Whiting PF, "QUADAS-2 : a revised tool for the quality assessment of diagnostic accuracy studies", Ann Intern Med, 155, pp.529~536 (2011)
- Bedossa P, "An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group", Hepatology, 24, pp.289~293 (1996)
- Zhu X, "Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy", AST platelet ratio index and FIB-4 in patients with chronic HBV infection, 2011, pp.56, 2742~2749
- Verveer C, "Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C", Liver Int, 32, pp.622~628 (2012)
- Kim BK, "Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B", PLoS One, 7, pp.e35825~ (2012)
- Degos F, "Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis : a multicenter prospective study(the FIBROSTIC study)", J Hepatol, 53, pp.1013~1021 (2010)
- Cardoso AC, "Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C", Liver Int, 32, pp.612~621 (2012)
- Partlett C, "Random effects meta-analysis : Coverage performance of 95% confidence and prediction intervals following REML estimation", Stat Med, 36, pp.301~317 (2017)
- "MIDAS: Stata module for meta-analytical integration of diagnostic test accuracy studies. Statistical Software Components, Boston College Department of Economics"[URL]
- Egger M, "Bias in meta-analysis detected by a simple, graphical test", BMJ, 315, pp.629~634 (1997)
- Shi L, "The trim-and-fill method for publication bias : practical guidelines and recommendations based on a large database of meta-analyses", Medicine(Baltimore), 98, pp.e15987~ (2019)
- Kim MN, "Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis", Hepatology, 61, pp.1851~1859 (2015)
- Jung KS, "Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement(FibroScan)", Hepatology, 53, pp.885~894 (2011)
- Kim BK, "Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test", Hepatology, 60, pp.1911~1919 (2014)
- Kim HS, "Association between level of fibrosis, rather than antiviral regimen, and outcomes of patients with chronic hepatitis B", Clin Gastroenterol Hepatol, 14, pp.1647~1656 (2016)
- Lee HW, "An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia", Liver Int, 40, pp.1736~1743 (2020)
- Jeon MY, "Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis", Hepatol Int, 11, pp.268~276 (2017)
- Chon YE, "Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly", Clin Mol Hepatol, 29, pp.120~134 (2023)
- Tsochatzis EA, "New therapeutic paradigm for patients with cirrhosis", Hepatology, 56, pp.1983~1992 (2012)
- Arena U, "Acute viral hepatitis increases liver stiffness values measured by transient elastography", Hepatology, 47, pp.380~384 (2008)
- Millonig G, "Extrahepatic cholestasis increases liver stiffness(FibroScan)irrespective of fibrosis", Hepatology, 48, pp.1718~1723 (2008)
- Millonig G, "Liver stiffness is directly influenced by central venous pressure", J Hepatol, 52, pp.206~210 (2010)
- Bardou-Jacquet E, "Effect of alcohol consumption on liver stiffness measured by transient elastography", World J Gastroenterol, 19, pp.516~522 (2013)
- Wu CY, "Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B : a nationwide cohort study", Gastroenterology, 147, pp.143~151 (2014)
- Lok AS, "Antiviral therapy for chronic hepatitis B viral infection in adults : A systematic review and meta-analysis", Hepatology, 63, pp.284~306 (2016)
- Korean Association for the Study of the Liver(KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clin Mol Hepatol, 28, pp.276~331 (2022)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)